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Edited by Varda RotterAbstract The range of BRCA1/BRCA2 gene mutations is
diverse and the mechanism accounting for this heterogeneity is
obscure. To gain insight into the endogenous mutational mecha-
nisms involved, we evaluated the association of speciﬁc sequences
(i.e. CpG/CpNpG motifs, homonucleotides, short repeats) and
mutations within the genes. We classiﬁed 1337 published muta-
tions in BRCA1 (1765 BRCA2 mutations) for each speciﬁc
sequence, and employed computer simulation combined with
mathematical calculations to estimate the true underlying ten-
dency of mutation occurrence. Interestingly, we found no muta-
tional bias to homonucleotides and repeats in deletions/insertions
and substitutions but striking bias to CpG/CpNpG in substitu-
tions in both genes. This suggests that methylation-dependent
DNA alterations would be a major mechanism for mutagenesis.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Gene mutation1. Introduction
Breast and ovarian cancer are the leading causes of cancer
death among women, with a lifetime risk of about 12.5%
and 1.5%, respectively. BRCA1 and BRCA2 are the most
important cancer susceptibility genes found in the diseases.
Germline mutations of the BRCA1/BRCA2 are responsible
for 30–40% of familial breast cancer cases [1]. Familial ovarian
cancer comprises at least 10% of cases.
BRCA1 (17q12-21) comprises over 70 kb of genomic DNA
and contains 22 coding exons, which encodes a 7.8 kb tran-
script [2]. BRCA2 (13q12-13) consists of 26 coding exons,
which are transcribed into a 11–12 kb mRNA [3]. To date,
more than 1337 diﬀerent mutations in BRCA1 (1765 BRCA2
mutations) have been reported which are clearly associated
with cancer susceptibility. These mutations and associated*Corresponding author. Fax: +852 2559 9114.
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doi:10.1016/j.febslet.2007.08.061data have been listed in the Human Gene Mutation Database
(HGMD) http://archive.uwcm.ac.uk/uwcm/mg/hgmd) and the
Breast Cancer Information Core (BIC) in the National Human
Genome Research Institute (http://research.nhgri.nih.gov/
projects/bic/) [3]. The most prominent subclasses of these
mutations are single base substitution, small deletion and
insertion. The range of gene mutations is diverse and only a
few recurrent mutations have been identiﬁed. The causes for
the heterogeneity of molecular defects in these genes are not
clear. However, there was evidence showing that speciﬁc nucle-
otide sequences (i.e. homonucleotides, short repeats, CpG/
CpNpG motifs) could serve as common hotspots to mutagen-
esis in tumor suppressor genes, for example p53, retinoblas-
toma and neuroﬁbromatosis (NF1) [4–9].
To gain insight into the endogenous mutational mechanisms
involved, we would like to know whether the speciﬁc sequences
signiﬁcantly associate with mutations within the BRCA1 and
BRCA2 genes. We developed a novel mathematical and com-
putational approach which gives quantitative estimation of
the association between simulated mutation events and speciﬁc
sequences. This also excludes the possibility that speciﬁc
sequences have been mutated by chance or because they are
abundant in the genes.2. Materials and methods
2.1. Data collection and mutation classiﬁcation
BRCA1 and BRCA2 gene mutations were retrieved from HGMD
database at http://archive.uwcm.ac.uk/uwcm/mg/hgmd and BIC data-
base at http://research.nhgri.nih.gov/projects/bic/ (last updated on
November 2006). These entries comprise mutations with and without
documented disease phenotype. We concluded from v2 test that the
occurrence of the ﬁve speciﬁc sequences (HO, R(0), R(1), R(2) and
CpG/CpNpG) (see below for annotation) did not diﬀer between muta-
tions with or without pathological signiﬁcance. Thus, we included all
the mutations listed for larger size of our dataset. We have 1337
(1765) diﬀerent BRCA1 (BRCA2) mutations including 764 (1135) sub-
stitutions, 415 (465) small deletions and 158 (165) insertions. All sub-
stitutions listed in the databases are non-synonymous which leads to
amino acid replacement.
Classiﬁcation analysis was performed by localizing mutations to the
cDNA sequences according to GenBank entries U14680 and U43746
for BRCA1 and BRCA2, respectively, and then identifying the nucleo-
tides ﬂanking the mutation sites. The inﬂuence of CpG/CpNpG motifs,
homonucleotides (HO) (e.g. GGGG) and short repeats, which include
direct repeats (e.g. (AG)n) and inverted repeats (e.g. AGGA), on each
mutation type (substitution, insertion and deletion) was assessed. Ourblished by Elsevier B.V. All rights reserved.
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given in Rodenhiser et al. [9,10]. Since mutation sites were found to
be only signiﬁcantly associated within very short distance to the nearby
repeats [11–13], repeats with more than two nucleotides in-between
were not taken into account in this study. Therefore, we denoted the
class of short repeats without any gaps by R(0) (e.g. CTCT), while
those with single gap by R(1) (e.g. GTTAGTT) or two gaps by R(2)
(e.g. ACTGAC). Also, a single mutation could be classiﬁed into more
than one speciﬁc sequences (e.g. ACCAﬁ ACTA as both HO and
R(0)), as a mutation might be caused independently by more than
one mechanism [14].
2.2. Computer simulation
Because the distribution of recorded mutations was highly non-uni-
form, and multiple mutations occurring at a same place could often be
observed, we constructed a mutation model that could incorporate this
phenomenon by assuming that the probability of having mutation
would be greater at site with recorded mutations. Let the number of
nucleotide positions which have mutation record be NA and those
without be NB. Therefore, NB is simply equal to the total length of
the gene minus NA. In this model, we assumed that P = 1/(aNA + NB)
and aP are the probability for a mutation to take place at a position
without or with mutation record respectively, where a (P 1) is the
mutation weighting. In this study, a was taken as: 1, 10, 20 or 30.
When a is equal to 1, the probability of a mutation to occur at any
position within the gene is the same, which corresponds to a uniform
distribution and we took this case as our natural starting point. As
the value of a increase, the probability of mutation to occur at a
recorded position increases. This mimics the non-uniform distribution
of a real situation. Since a linear relation was found between simulated
counts and a when a 6 30, we did not consider a value of a > 30.
A position where the simulated mutation would occur was randomly
selected with a built-in function RAND in Microsoft Excel, which pro-
duces random values between 0 and 1 in equal chance, referred to as
interval [0,1]. We modiﬁed the generation process with a to obtain ran-
dom numbers in spatially non-uniform manner. We divided the inter-
val [0,1] into (aNA + NB) subintervals of equal length and assigned a
intervals to each nucleotide position with mutation record and oneA. BRCA1
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Fig. 1. Schematic of the distribution of mutations collected in the dataset fo
scale for individual gene and the exons are represented as numbers that are ei
for each exon are shown below the boxes.interval to each position without record. A random number from the
interval [0,1] was selected which indicated the site for simulation.
And the chance to simulate mutation at site with record would increase
with the value of a.
A substitution was simulated based on the nucleotide-to-nucleotide
substitution rates estimated from the observed data in our dataset. The
length and base composition of inserted/deleted nucleotide fragment
for simulation were determined by the relative frequencies of nucleo-
tide and fragment lengths from the dataset. For each mutation weight-
ing a, we performed 200000 simulations for each mutation type.2.3. Mathematical calculations
Equations were derived and applied to our simulated data. Let p and
q be the probability of having a speciﬁc sequence at a position with and
without recorded respectively. Close value of p and q implies that the
mutation type is not biased to the speciﬁc sequence, whereas signiﬁcant
diﬀerence between the two values implicates bias. We then performed
T simulations of each mutation type. Based on the assumption that the
probability of having a mutation would be higher site with mutation
recorded, the expected number of mutations associated with the spe-
ciﬁc pattern can be expressed asapNA þ qNB
aNA þ NB
 
Twhere a is the mutation weighting. Let Ca be the number of counts of
the speciﬁc sequence that has occurred in the simulation when the
mutation weighting is a. For each combination of mutation weighting
a1 and a2, the values of p and q could be obtained by solving the fol-
lowing system of equationsa1pNA þ qNB
a1NA þ NB
 
T ¼ Ca1
a2pNA þ qNB
a2NA þ NB
 
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To show the signiﬁcance of the diﬀerence between p and q, signiﬁ-
cance test for comparing proportions was performed. P < 0.05 was
considered statistically signiﬁcant.3. Results
3.1. Mutation spectra of BRCA1 and BRCA2
Fig. 1 is the schematic showing the distribution of mutations
found in the two genes. The frequency of mutations increased
with exon size, where 62.3% and 47.02% of all mutations were
located in exon 11 of BRCA1 and BRCA2, respectively
(Fig. 1). Exon 4 of BRCA1 was omitted as it was found to
be an Alu element and cloning artifact during isolation. This
exon is rarely expressed and its insertion introduces a prema-
ture stop codon [15].
3.2. Local DNA-sequence environment ﬂanking short deletions
and insertions
In an attempt to discern the nucleotide sequences ﬂanking
each mutation, nucleotide context around the mutation site
was examined. Tables 1 and 2 show representative data ran-
domly chosen from our analyses, with classiﬁed mutations
for each speciﬁc sequence in the BRCA1 and BRCA2 genes,
respectively. Table 3 shows the summarized data from our
analysis. Our results showed that 86% deletions in BRCA1Table 1
Representative substitutions, deletions and insertions in the BRCA1 gene
Exon Mutationa DNA sequencea
A. Substitutionsb
(i) Substitutions associated with homonucleotides
5 G331A CAAAAGGAGCCT
11 A1260T TTCAGAAAGTTA
(ii) Substitutions associated with repeats
5 G259A TTTGCATGCTG
7 A433G ACAGCTATAAT
(iii) Substitutions associated with CpG/CpNpG motifs
11 C1740T CGGAGCAGAAT
11 C2715T AAAGCGCCAG
B. Deletionsc
(i) Deletions associated with homonucleotides
11 916gelTT GTTCTGTTTCAA
16 5063delA CAACAAAAGAAT
(ii) Deletions associated with repeats
11 1477delAG CAGTAGAGAGTAA
12 4286delT TCAGAGTGACATT
C. Insertionsd
(i) Insertions associated with homonucleotides
8 613insT AACTCTTGAGG
11 3376insT TAGATTTAGGG
(ii) Insertions associated with repeats
11 3331insG AGCAGAGACTAG
11 3768insA ACTTATACTAGT
See the HGMD database for corresponding references.
aMutation nomenclature is according to GenBank accession number U1468
bThe substituted nucleotide is underlined and the association with the speciﬁ
cThe deleted nucleotide is underlined and the association with the speciﬁc se
dThe inserted nucleotide is underlined and the association with the speciﬁc swere associated with HO. Short repeats were predominant
features in the sequence environment surrounding BRCA1
small deletions (71% for R(0), 85% for R(1), 90% for R(2)).
Seventy-two percent insertions occurred at the site of HO while
45% (R(0)), 67% (R(1)), 77% (R(2)) insertions were found at
short repeats.
There were 465 deletions and 165 insertions in the dataset of
the BRCA2 gene. Eighty-four percent deletions and 86% inser-
tions were found in HO. The frequencies of short repeats at
deletion were 67%, 87% and 93%, and at insertions were
49%, 66% and 76% for R(0), R(1), and R(2), respectively.
There was no diﬀerence in the frequency of mutations per
speciﬁc nucleotide sequence among the various exons in both
the BRCA1 and BRCA2 genes (see Tables S1 and S2 in the
Supplementary material).
3.3. Local DNA-sequence environment ﬂanking substitutions
Sixty-seven percent of BRCA1 substitutions were associated
with HO. The percentage of short repeats were 66%, 87% and
92% for R(0), R(1) and R(2), respectively. In contrast, only
22% substitutions were detected in CpG/CpNpG motifs (Table
3). In addition, we also observed a preponderance of transi-
tions (58%) over transversions (42%) (data not shown). Most
of these transitions could be attributed to the hypermutability
of the CpG dinucleotide to TG or CA. This type of transition
mutations accounts for 34.2% of all substitutions and for
58.9% of transitions.Predicted A.A change Phenotype
Arg-Lys (R71K) Breast and/or ovarian cancer
Lys-Term (K381X) Breast cancer
Cys-Tyr (C47Y) Breast and/or ovarian cancer
Tyr-Cys (Y105C) Breast cancer
Gln-Term (Q541X) Breast cancer
Arg-Cys (R866C) Breast and/or ovarian cancer
Breast cancer
Ovarian cancer
Ovarian cancer
Breast and/or ovarian cancer
Breast and/or ovarian cancer
Ovarian cancer
Breast cancer
Ovarian cancer
0.
c sequence motifs are highlighted as bold.
quence motifs are highlighted as bold.
equence motifs are highlighted as bold.
Table 2
Representative substitutions, deletions and insertions in the BRCA2 gene
Exon Mutation a DNA sequencea Predicted A.A change Phenotype
A. Substitutionsb
(i) Substitutions associated with homonucleotides
3 G361T TAATTCTGAACCTG Glu-Term Breast and/or ovarian cancer
11 A3058T CAATTAAAAAAGA Lys-Term Breast cancer
(ii) Substitutions associated with repeats
7 G809A TATGTCTTGGTCAAGT Trp-Term Breast cancer
10 T1742C AAAGTCTATATTCAG Ile-Thr Breast cancer
(iii) Substitutions associated with CpG/CpNpG motifs
11 C6187T GTCCAGGTATCAG Gln-Term Breast cancer
15 C7708T TATGCGAATTAAGA Arg-Term Breast cancer
B. Deletionsc
(i) Deletions associated with homonucleotides
3 432delA AAGGAAACCATCT Breast and/or ovarian cancer
11 4084delAAA GTGAAAAAAATAAT Breast cancer
(ii) Deletions associated with repeats
2 277delAC TTTAAGACACGCTG Breast cancer
10 1900delA AATTTAATTGATA Breast cancer
C. Insertionsd
(i) Insertions associated with homonucleotides
11 3979insA GGAAAACTTCTGCA Ovarian cancer
18 8299insTT GTGTTTTTCTGACAT Breast and/or ovarian cancer
(ii) Insertions associated with repeats
7 767insAT AACATATATTTCTGAA Breast and/or ovarian cancer
19 8664insA GATGGAAGGAAAT Breast cancer
See the HGMD database for corresponding references.
aMutation nomenclature is according to GenBank accession number U43746.
bThe substituted nucleotide is underlined and the association with the speciﬁc sequence motifs are highlighted as bold.
cThe deleted nucleotide is underlined and the association with the speciﬁc sequence motifs are highlighted as bold.
dThe inserted nucleotide is underlined and the association with the speciﬁc sequence motifs are highlighted as bold.
Table 3
Frequency of homonucleotides, short repeats and CpG/CpNpG motifs associated with deletions,insertions and substitutions in BRCA1 and BRCA2
genes
Mutation type HO R(0) R(1) R(2) CpG/CpNpG Total
Substitutions BRCA1 515 (67%) 503 (66%) 666 (87%) 704 (92%) 168 (22%) 764
BRCA2 780 (69%) 782 (69%) 970 (85%) 1039 (92%) 225 (20%) 1135
Deletions BRCA1 356 (86%) 293 (71%) 351 (85%) 375 (90%) NA 415
BRCA2 391 (84%) 312 (67%) 403 (87%) 431 (93%) NA 465
Insertions BRCA1 114 (72%) 71 (45%) 106 (67%) 121 (77%) NA 158
BRCA2 142 (86%) 81 (49%) 109 (66%) 125 (76%) NA 165
NA, not applicable.
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BRCA2 gene were associated with HO. The observed percent-
age of repeats were 69% for R(0), 85% for R(1) and 92% for
R(2). Twenty percent were detected in CpG/CpNpG motifs
(Table 3). An excess of transitional nucleotide changes was
also observed in the BRCA2 gene, with 61% transition over
39% transversion (data not shown).
Taken together, these observations showed that homonucle-
otides and repeats were most frequent for deletions/insertions
and substitutions, whereas CpG/CpNpG motifs only had a
moderate correlation. Although these results are consistent
with many previous reports [9–11] based on percentage counts,they may not reﬂect the true underlying tendency of mutation
occurrence since this tendency can be aﬀected by a greater
number of these sequences within the genes.
3.4. Simulations of mutations
To better deﬁne whether there was bias of mutation events
towards certain speciﬁc sequences, we employed a computer
simulation model which generated uneven distribution of
mutations by incorporation of mutation weighting a. For each
combination of mutation weighting a and mutation type,
200000 samples were generated and the proportion of simu-
lated mutations associated with the speciﬁc sequences was
Table 6
The probabilities p and q calculated from simulated data
HO R(0) R(1) R(2) CpG/CpNpG
SUB BRCA1 p 0.72a 0.68 0.87 0.92 0.22a
q 0.79a 0.68 0.87 0.92 0.11a
BRCA2 p 0.73a 0.69 0.86 0.92 0.19a
q 0.79a 0.68 0.86 0.92 0.09a
DEL BRCA1 p 0.85 0.72 0.87 0.92 NA
q 0.85 0.72 0.88 0.93 NA
BRCA2 p 0.83 0.70 0.87 0.93 NA
q 0.88 0.72 0.87 0.93 NA
INS BRCA1 p 0.61 0.46 0.69 0.79 NA
q 0.64 0.52 0.74 0.84 NA
BRCA2 p 0.66 0.49 0.70 0.80 NA
q 0.67 0.51 0.72 0.82 NA
NA, not applicable.
aSigniﬁcant diﬀerence between p and q.
Table 4
Results of simulated mutations with varied mutation weighting a of the
BRCA1 gene
Mutation
weighting a
HO R(0) R(1) R(2) CpG/
CpNpG
SUB (764) 1 0.78 0.68 0.86 0.92 0.12
10 0.75 0.68 0.87 0.92 0.17
20 0.74 0.68 0.87 0.92 0.19
30 0.73 0.68 0.87 0.92 0.20
Chance in
real dataset
0.67 0.66 0.87 0.92 0.22
DEL (415) 1 0.86 0.72 0.87 0.93 N.A
10 0.85 0.72 0.87 0.93 N.A
20 0.85 0.72 0.87 0.92 N.A
30 0.85 0.72 0.87 0.93 N.A
Chance in
real dataset
0.86 0.71 0.85 0.90 N.A
INS (158) 1 0.64 0.52 0.74 0.84 N.A
10 0.64 0.51 0.73 0.83 N.A
20 0.63 0.50 0.72 0.82 N.A
30 0.63 0.49 0.72 0.82 N.A
Chance in
real dataset
0.72 0.45 0.67 0.77 N.A
NA, not applicable.
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with increasing mutation weighting a for BRCA1 and BRCA2,
respectively. The chance of occurrence increases with the value
and ‘‘1’’ represents maximal chance. An increasing trend of
substitutions associated with CpG/CpNpG motifs could be
clearly observed when the mutation weighting a was gradually
increased for both the BRCA1 gene (1.8-fold) and BRCA2
gene (2-fold). This result suggests that these motifs are pre-
ferred sites for substitutions. It is noteworthy that there was
also a moderate decreased chance of substitutions associated
with the HO motifs. On the contrary, there was no signiﬁcant
change in the numbers of events in deletions and insertions
associating with any speciﬁc sequences. The simulated countsTable 5
Results of simulated mutations with varied mutation weighting a of the
BRCA2 gene
Mutation
weighting a
HO R(0) R(1) R(2) CpG/
CpNpG
SUB (1135) 1 0.78 0.68 0.86 0.92 0.10
10 0.76 0.69 0.86 0.92 0.14
20 0.75 0.69 0.86 0.92 0.16
30 0.75 0.69 0.86 0.92 0.17
Chance in
real dataset
0.69 0.69 0.85 0.92 0.20
DEL (465) 1 0.88 0.72 0.87 0.93 NA
10 0.87 0.71 0.87 0.93 NA
20 0.86 0.71 0.87 0.93 NA
30 0.86 0.71 0.87 0.93 NA
Chance in
real dataset
0.84 0.67 0.87 0.93 NA
INS (165) 1 0.67 0.51 0.72 0.82 NA
10 0.67 0.51 0.72 0.82 NA
20 0.67 0.51 0.72 0.82 NA
30 0.67 0.50 0.72 0.82 NA
Chance in
real dataset
0.86 0.49 0.66 0.76 NA
NA, not applicable.in these cases remained steady even when the mutation weight-
ing a increased.
3.5. Demonstration of relationship by mathematical models
To further ascertain the relationship among simulated muta-
tions and surrounding nucleotide environment, we employed
mathematical equations and compared the value of p and q ob-
tained (Table 6), which can reﬂect the likelihood of mutational
bias towards surrounding nucleotides compositions. To show
the signiﬁcance of the diﬀerence between p and q, signiﬁcance
test for comparing proportions was performed. We noticed
that in both BRCA1 and BRCA2, p was signiﬁcantly larger
than q in CpG/CpNpG (P < 0.005). This suggested that
CpG/CpNpG occurred more frequently than expected. On
the other hand, p was smaller than q in HO (P < 0.005). No
signiﬁcant diﬀerence could be seen between the p and q values
for the other mutation types, indicating essentially no bias be-
tween these mutation events and the neighboring nucleotides.4. Discussion
BRCA1/BRCA2 gene mutations are extensively studied be-
cause of their importance in breast and/or ovarian cancer.
However, the mechanism(s) responsible for their mutagenesis
is largely unknown. Although a previous study has assessed
the signiﬁcance of speciﬁc sequences at mutational sites in
BRCA1 [10], the present study distinguishes itself in several
key aspects. First, the sample size of our datasets is greatly ex-
panded that allows statistically robust analysis. Our evaluation
was based on 1337 independent BRCA1 mutations compared
with 74 cases from the previous study [10]. Second, to our
knowledge, this is the ﬁrst study to analyze the nucleotides
sequences ﬂanking mutations of the BRCA2 gene. Third, we
adopted a stricter set of rules for classifying the mutations.
Finally, while the previous study was based on percentage
counts, we employed computational method with simulation
model to test whether these results reﬂect the true underlying
tendency of mutation occurrence.
One major ﬁnding of this study is that although there was
only a moderate correlation between substitutions and CpG/
CpNpG motifs, these mutational events were statistically
biased to the CpG/CpNpG motifs of both the BRCA1 and
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has largely been attributed to spontaneous deamination of 5-
methylcytosines to thymine. We also observed a preponder-
ance of transitions over transversions, suggesting a strong bias
towards TG or CA deamination products in the genes. These
data are coincident with in vitro evidence demonstrating
DNA methylation in the BRCA1 gene as a possible mechanism
to generate mutations at CpG/CpNpG motifs [10]. In fact,
exogenous chemical carcinogens have also been found to be
causative factors in methylation-mediated mutagenesis of the
CpG/CpNpG motifs [16,17], reﬂecting the motifs as muta-
tional hotspot causing human genetic disease and cancer
[18–20]. For example, mutations within CpG/CpNpG sites
represent 45–50% of p53 point mutations in colorectal cancer
[21], 20–25% of all Rb mutations [22] and 13–17% of all
APC mutations in colon cancer [23].
Since it has previously been reported that sequence slippage,
which occur in homonucleotides and short repeats, as another
possible means to generate substitution mutations [24,25], we
also assessed the frequency of mutations occurring at these
particular sequence elements. We found a downward (nega-
tive) mutation bias for substitutions at homonucleotides/
repeats was noted in the BRCA1 and BRCA2 genes, suggesting
that homonucleotides and short repeats are not the major con-
tributor to the generation of substitutions in the BRCA1 and
BRCA2 genes. One explanation might be that the mutational
bias towards next neighbors is conditional. The mutability of
a nucleotide has been found to be diﬀerent within diﬀerent
combinations of speciﬁc dinucleotides [26]. Of 16 combina-
tions, only half of them were shown to be favorable for substi-
tutions to occur [26]. This selectivity might be explicable by
reading frame-sensitive DNA-repair bias and DNA thermody-
namic stability, which in turn introduces mutation bias only at
speciﬁc codon position and DNA strand [13]. There is also
contradictory evidence showing only subtle contribution of
repetitive sequences surrounding substitution sites [13].
Apart from substitutions, the vast majority of BRCA1 and
BRCA2 mutations comprise short deletions and insertions. It
has been suggested that these two types of mutation share very
similar generative mechanisms mediated by homonucleotides
and repeats [27]. Although, we observed homonucleotides
and repeats were commonly associated with deletions and
insertions, the computer simulation with mathematical analy-
sis indicated that BRCA1 and BRCA2 deletions and insertions
were not caused by a general bias towards homonucleotides/re-
peats. We obtained the same conclusion even if we have taken
into account of other factors. For example, we have considered
other possibilities of repeats with more than two nucleotides
in-between (R(n); n > 2) [28]. As n increased (e.g. n = 3, 4,
and 5), there was an increase in mutations associated with re-
peat elements (95%, 96%, and 97%) but no diﬀerence was seen
between the p and q values (p = q = 0.95, 0.96, 0.97). More-
over, artifacts may appear with inclusion of the dinucleotide
repeat due to the abundance and high error frequency of this
repeat unit in one or more repeat lengths. To address this
problem, we repeated our analysis excluding the dinucleotide
repeats. Again, this did not alter the results obtained (see Table
S3 in the supplementary material). Thus, our results suggest
that the mutagenesis might be due to a previously unrecog-
nized or less common mechanism. Slippage repair may not
be the sole mechanism by which deletions and insertions occur.
In fact, it has previously been shown that sequence slippageaccounts for only about 30–50% of the observed mutations
[29]. However, despite the importance of this information, lit-
tle is known about the alternative mechanisms of mutation.
Quasi-palindromic sequences [30,31], symmetrics elements
[27], and ‘‘knot’’ (inversion of inverted repeats) [32] have been
shown to be involved in the mechanism of mutagenesis in cer-
tain circumstances.
In summary, this study signiﬁcantly extends the analysis of
BRCA mutations over existing data and methods to allow
comprehensive and unbiased identiﬁcation of speciﬁc nucleo-
tide sequences that are associated with BRCA mutagenesis.
The great advantage of the new algorithm used in this study
is that it allows both the observed and selective frequencies
of mutational events to be considered. Therefore, it can be ar-
gued against the possibility that mutations have occurred in a
speciﬁc nucleotide sequence simply by chance due to that
sequence relative abundance in the gene rather than because
of a causal connection. In our analyses, we have not only of-
fered additional support for the known patterns, which indi-
cates that our strategy is a valid approach, but also
unraveled new (or unusual) mechanisms that could have been
overlooked by traditional methods. Further studies on the pre-
cise mechanisms are undoubtedly an important area of inves-
tigation. The new algorithm presented is general and may
present a new paradigm for understanding the mutational
events for other genes. Our results also have signiﬁcant impli-
cations for genetic screening. At present, due to the large size
of the gene, the extremely heterogeneous mutations, and the
lack of high eﬃciency screening methods, the molecular diag-
nosis for BRCA1 and BRCA2 mutations has been onerous.
Since our data show that CpG/CpNpG motifs are signiﬁcantly
associated with BRCA1 and BRCA2 mutations, the search for
an unknown mutation could be predicted to some degree
based on the analysis of such motifs within the sequence.
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